Novo Holdings is making a significant move, doubling down on the Indian healthcare market with substantial investments. This strategic shift signals a strong belief in India's growth potential, particularly in specialized healthcare sectors.
Novo Holdings, the controlling entity behind the obesity drug giant Novo Nordisk, is shifting its focus towards India. They are targeting single-specialty hospitals and contract drug manufacturers, aiming to capitalize on the burgeoning healthcare landscape.
India, now the world's most populous nation, is witnessing a surge in demand for specialized medical services. Analysts and industry experts agree that these specialized amenities will be the cornerstone of the Indian healthcare market's future. The sector is also experiencing a boom, fueled by increased private and foreign investments.
Novo Holdings, boasting a massive 142 billion euros (approximately $165.60 billion) in assets under management by the end of 2024, is actively engaging with several Indian companies. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, revealed this in a recent interview. The company, which manages assets for the Novo Nordisk Foundation (one of the world's largest philanthropic organizations) and holds a 77% voting control in Novo Nordisk, is making significant strides.
"When we first started investing (in India), our average ticket size was $20 million-$30 million. Now, it's between $50 million and $125 million. So clearly, we're doing bigger deals," Kakar stated. To facilitate this expansion, Novo has established a dedicated team in Mumbai.
Their current focus includes specialized healthcare and complex drug manufacturing. Novo's largest investment in Asia to date is a minority stake in India's Manipal Hospitals, acquired in 2024.
Kakar identifies single-specialty hospitals – smaller facilities specializing in areas like oncology, mother and child health, and nephrology – as the "next phase" in hospital care. He notes a trend of healthcare services moving away from large hospitals.
The single-specialty hospital segment is projected to reach $40.14 billion by 2032, up from $16.2 billion in 2024. This growth is driven by increasing health awareness and the prevalence of chronic diseases, according to Credence Research.
Novo is also exploring investments in contract drug manufacturers, particularly those specializing in complex biological drugs used to treat severe illnesses like cancer. Other areas of interest include senior care and step-down care, which provides support for patients recovering from major surgeries or cardiac events.
But here's where it gets interesting: The shift towards specialized care could potentially reshape the healthcare landscape, making it more accessible and tailored to specific needs.
And this is the part most people miss: The significant investment size increase indicates Novo Holdings' strong confidence in the Indian market's potential.
What do you think? Will this focus on specialized healthcare and complex drug manufacturing prove to be a successful strategy for Novo Holdings in India? Share your thoughts in the comments below!
